Seattle, Washington, U.S., September 24, 2026
Atossa Therapeutics Inc. announced that its Chief Executive Officer and Founder, Dr. Steven Quay, will participate in a panel discussion at the Aging Research at Drug Discovery (ARDD) 2026 conference, focusing on clinical trials and regulatory pathways for diseases associated with aging. The event is scheduled to take place in Copenhagen, Denmark, from September 29 to October 2, 2026. Dr. Quay is expected to contribute to discussions examining challenges associated with translating aging research into clinical development programs, including considerations surrounding clinical trial design, regulatory strategies and therapeutic development. Atossa is a clinical-stage biopharmaceutical company developing therapies for breast cancer and other diseases, with its research and development activities focused on advancing novel therapeutic approaches. The company’s participation in ARDD 2026 places its leadership among researchers, clinicians, drug developers and regulatory experts discussing the development of medicines for age-related diseases.
Atossa CEO to Discuss Clinical Trial Pathways
Dr. Quay is scheduled to participate in a panel titled “Clinical Trials and Regulatory Pathways for Diseases of Aging.” The session is expected to address the scientific and regulatory considerations involved in developing treatments for diseases that become more prevalent or clinically significant with advancing age. Clinical development for aging-related conditions can involve complex patient populations, multiple disease mechanisms and long-term treatment considerations. Regulatory pathways must also account for the specific characteristics of each disease and the clinical endpoints needed to demonstrate the safety and efficacy of an investigational therapy. Discussions at ARDD 2026 are expected to bring together perspectives from pharmaceutical and biotechnology companies, academic researchers and regulatory specialists working across the aging research ecosystem.
ARDD 2026 Focuses on Aging Drug Discovery
The ARDD conference brings together members of the aging research and drug-development communities to discuss advances in biology, therapeutics and translational medicine. The 2026 meeting is focused on scientific and clinical developments relevant to extending healthy lifespan and addressing diseases associated with aging. Topics across the conference include mechanisms of aging, drug discovery, biomarkers, clinical development and regulatory considerations. The participation of industry leaders such as Dr. Quay reflects the growing interaction between basic aging research and the pharmaceutical development process. Moving discoveries from laboratory research into clinical trials requires evidence demonstrating that a potential therapeutic target can translate into a meaningful clinical benefit, making trial design and regulatory planning important components of the development process.
Advertisement
Atossa Advances Clinical-Stage Drug Development
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines, with programs including therapies targeting breast cancer. The company has emphasized the development of treatments designed to address areas of significant unmet medical need. Its research programs involve clinical and preclinical development activities intended to generate evidence supporting potential therapeutic applications. Through participation in scientific and industry forums such as ARDD 2026, Atossa’s leadership can engage with researchers and drug developers on broader challenges affecting clinical-stage biotechnology companies, including regulatory requirements, clinical trial methodology and the translation of scientific discoveries into potential medicines.
The ARDD 2026 panel provides an opportunity to discuss the broader drug-development challenges associated with diseases of aging, an area receiving increasing attention from the biomedical research community. As researchers identify biological mechanisms associated with aging and age-related disease, clinical developers must determine how these discoveries can be evaluated through appropriately designed human studies and regulatory pathways. Atossa Therapeutics’ participation in the discussion highlights the company’s engagement with the wider clinical-development and biomedical research community. The panel is expected to explore how scientific advances can be translated into clinical research while addressing the regulatory requirements necessary for developing new therapies for aging-related diseases.
Source: Atossa Therapeutics press release
